IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.
Int J Mol Sci. 2022 Jan 8;23(2):682. doi: 10.3390/ijms23020682.
The retinal pigmented epithelium (RPE) plays a pivotal role in retinal homeostasis. It is therefore an interesting target to fill the unmet medical need of different retinal diseases, including age-related macular degeneration and Stargardt disease. RPE replacement therapy may use different cellular sources: induced pluripotent stem cells or embryonic stem cells. Cells can be transferred as suspension on a patch with different surgical approaches. Results are promising although based on very limited samples. In this review, we summarize the current progress of RPE replacement and provide a comparative assessment of different published approaches which may become standard of care in the future.
视网膜色素上皮(RPE)在视网膜稳态中起着关键作用。因此,它是一个很有吸引力的靶点,可以满足不同视网膜疾病(包括年龄相关性黄斑变性和 Stargardt 病)未满足的医学需求。RPE 替代疗法可以使用不同的细胞来源:诱导多能干细胞或胚胎干细胞。细胞可以作为悬浮液转移到带有不同手术方法的贴片上。尽管基于非常有限的样本,但结果是有希望的。在这篇综述中,我们总结了 RPE 替代的最新进展,并对不同已发表的方法进行了比较评估,这些方法可能成为未来的标准治疗方法。